Clonal vaccinia virus grown in cell culture as a new smallpox vaccine
Authors
Weltzin, RichardLiu, Jian
Pugachev, Konstantin V.
Myers, Gwendolyn A.
Coughlin, Brie
Blum, Paul S.
Nichols, Richard
Johnson, Casey
Cruz, John
Kennedy, Jeffrey S.
Ennis, Francis A.
Monath, Thomas P.
UMass Chan Affiliations
Department of Medicine, Division of Infectious Diseases and ImmunologyCenter for Infectious Disease and Vaccine Research
Document Type
Journal ArticlePublication Date
2003-09-01Keywords
ImmunityImmunology and Infectious Disease
Immunology of Infectious Disease
Infectious Disease
Metadata
Show full item recordAbstract
Although the smallpox virus was eradicated over 20 years ago, its potential release through bioterrorism has generated renewed interest in vaccination. To develop a modern smallpox vaccine, we have adapted vaccinia virus that was derived from the existing Dryvax vaccine for growth in a human diploid cell line. We characterized six cloned and one uncloned vaccine candidates. One clone, designated ACAM1000, was chosen for development based on its comparability to Dryvax when tested in mice, rabbits and monkeys for virulence and immunogenicity. By most measures, ACAM1000 was less virulent than Dryvax. We compared ACAM1000 and Dryvax in a randomized, double-blind human clinical study. The vaccines were equivalent in their ability to produce major cutaneous reactions ('takes') and to induce neutralizing antibody and cell-mediated immunity against vaccinia virus.Source
Nat Med. 2003 Sep;9(9):1125-30. Epub 2003 Aug 17. doi:10.1038/nm916. Link to article on publisher's siteDOI
10.1038/nm916Permanent Link to this Item
http://hdl.handle.net/20.500.14038/35058PubMed ID
12925845Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1038/nm916